

CLEARBRIDGE HEALTH LIMITED
(Incorporated in the Republic of Singapore)
(Company Registration No. 201001436C)

**NOTIFICATION OF A CIVIL SUIT FILED BY A JOINT VENTURE PARTNER OF AN INDIRECT
SUBSIDIARY – DISMISSAL OF SUIT**

The board of directors of Clearbridge Health Limited (the "**Company**") refers to the Company's announcements dated 31 May 2020 and 23 August 2020 in relation to the Suit (the "**Announcements**"). Unless otherwise defined, capitalised terms in this announcement shall have the same meaning as ascribed to them in the Announcements.

The Group wishes to announce that at a hearing held on Monday, 7 June 2021, at the North Jakarta District Court (the "**North Jakarta Court**") in relation to the Suit (case No.227/Pdt.G/2020/PN.JKT.UTR.) filed by TMN against, among others, TMJ (as the Defendant I) and CBMA (as the Defendant II), the North Jakarta Court dismissed the Suit based on the reason that pursuant to the shareholders agreement among TMJ's shareholders dated 23 April 2018, the North Jakarta District Court does not have the jurisdiction to hear the Suit. The North Jakarta Court also directed TMN to pay the court administrative fees of IDR1,653,250.00 (approximately S\$153.35, based on an exchange rate of IDR10.781.23 to S\$1.00).

TMN may submit an appeal within 14 days after 7 June 2021.

The Company will make such further announcements as may be necessary and appropriate.

Shareholders and potential investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants, or other professional advisers if they are in doubt about the actions that they should take.

BY ORDER OF THE BOARD

YEE PINH JEREMY
Executive Director and Chief Executive Officer

8 June 2021

*This announcement has been prepared by the Company and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "**Sponsor**"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement. The contact person for the Sponsor is Mr David Tham, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*